It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COR’s FA Score shows that 1 FA rating(s) are green whileFOCL’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COR’s TA Score shows that 4 TA indicator(s) are bullish while FOCL’s TA Score has 4 bullish TA indicator(s).
COR (@Medical Distributors) experienced а +2.41% price change this week, while FOCL (@Medical Distributors) price change was +3.51% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was +1.12%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was -6.17%.
COR is expected to report earnings on Aug 05, 2026.
FOCL is expected to report earnings on Aug 26, 2026.
Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
| COR | FOCL | COR / FOCL | |
| Capitalization | 54.8B | 177M | 30,960% |
| EBITDA | 5.03B | -25.53M | -19,709% |
| Gain YTD | -16.269 | 43.465 | -37% |
| P/E Ratio | 21.58 | N/A | - |
| Revenue | 329B | 74.1M | 443,995% |
| Total Cash | 2.18B | 15M | 14,507% |
| Total Debt | 12.4B | 27.8M | 44,604% |
COR | FOCL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 35 | 19 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 60 Fair valued | 98 Overvalued | |
PROFIT vs RISK RATING 1..100 | 35 | 100 | |
SMR RATING 1..100 | 11 | 99 | |
PRICE GROWTH RATING 1..100 | 60 | 37 | |
P/E GROWTH RATING 1..100 | 87 | 99 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
COR's Valuation (60) in the Real Estate Investment Trusts industry is somewhat better than the same rating for FOCL (98) in the Biotechnology industry. This means that COR’s stock grew somewhat faster than FOCL’s over the last 12 months.
COR's Profit vs Risk Rating (35) in the Real Estate Investment Trusts industry is somewhat better than the same rating for FOCL (100) in the Biotechnology industry. This means that COR’s stock grew somewhat faster than FOCL’s over the last 12 months.
COR's SMR Rating (11) in the Real Estate Investment Trusts industry is significantly better than the same rating for FOCL (99) in the Biotechnology industry. This means that COR’s stock grew significantly faster than FOCL’s over the last 12 months.
FOCL's Price Growth Rating (37) in the Biotechnology industry is in the same range as COR (60) in the Real Estate Investment Trusts industry. This means that FOCL’s stock grew similarly to COR’s over the last 12 months.
COR's P/E Growth Rating (87) in the Real Estate Investment Trusts industry is in the same range as FOCL (99) in the Biotechnology industry. This means that COR’s stock grew similarly to FOCL’s over the last 12 months.
| COR | FOCL | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 64% | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 51% | 3 days ago 86% |
| Momentum ODDS (%) | 3 days ago 61% | N/A |
| MACD ODDS (%) | 3 days ago 62% | 3 days ago 79% |
| TrendWeek ODDS (%) | 3 days ago 62% | 3 days ago 73% |
| TrendMonth ODDS (%) | 3 days ago 63% | 3 days ago 78% |
| Advances ODDS (%) | 3 days ago 61% | 3 days ago 73% |
| Declines ODDS (%) | 19 days ago 42% | 12 days ago 86% |
| BollingerBands ODDS (%) | 3 days ago 48% | 3 days ago 79% |
| Aroon ODDS (%) | N/A | 3 days ago 79% |
A.I.dvisor tells us that FOCL and AORT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that FOCL and AORT's prices will move in lockstep.
| Ticker / NAME | Correlation To FOCL | 1D Price Change % | ||
|---|---|---|---|---|
| FOCL | 100% | +0.43% | ||
| AORT - FOCL | 29% Poorly correlated | -2.43% | ||
| AVNS - FOCL | 21% Poorly correlated | -0.08% | ||
| UFPT - FOCL | 20% Poorly correlated | -1.53% | ||
| SENS - FOCL | 20% Poorly correlated | -2.05% | ||
| STXS - FOCL | 16% Poorly correlated | +1.10% | ||
More | ||||